Cantor Fitzgerald Weighs in on NeuroPace FY2026 Earnings

NeuroPace, Inc. (NASDAQ:NPCE) – Cantor Fitzgerald issued their FY2026 earnings estimates for shares of NeuroPace in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst R. Osborn anticipates that the company will post earnings per share of ($0.61) for the year. Cantor Fitzgerald has a “Overweight” rating and a $17.00 price objective on the stock. The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, May 13th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.05. The firm had revenue of $22.52 million for the quarter, compared to the consensus estimate of $21.85 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%.

Several other analysts also recently commented on the stock. HC Wainwright initiated coverage on shares of NeuroPace in a report on Wednesday, May 28th. They set a “buy” rating and a $18.00 target price on the stock. JPMorgan Chase & Co. raised their target price on shares of NeuroPace from $14.00 to $16.00 and gave the stock an “overweight” rating in a report on Wednesday, May 14th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $15.50.

NeuroPace Stock Performance

Shares of NPCE stock opened at $11.83 on Tuesday. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. The company has a market capitalization of $388.01 million, a P/E ratio of -11.83 and a beta of 2.03. The company’s 50 day moving average price is $12.89 and its two-hundred day moving average price is $12.37. NeuroPace has a 52 week low of $5.45 and a 52 week high of $18.98.

Institutional Trading of NeuroPace

Hedge funds and other institutional investors have recently made changes to their positions in the business. Northern Trust Corp raised its holdings in shares of NeuroPace by 15.7% in the fourth quarter. Northern Trust Corp now owns 184,847 shares of the company’s stock valued at $2,068,000 after purchasing an additional 25,035 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of NeuroPace by 440.4% in the fourth quarter. JPMorgan Chase & Co. now owns 64,826 shares of the company’s stock valued at $725,000 after purchasing an additional 52,829 shares during the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of NeuroPace in the fourth quarter valued at $639,000. Point72 Asset Management L.P. bought a new position in shares of NeuroPace in the fourth quarter valued at $369,000. Finally, Jane Street Group LLC bought a new position in shares of NeuroPace in the fourth quarter valued at $1,120,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, major shareholder Orbimed Advisors Llc sold 168,136 shares of NeuroPace stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $15.85, for a total value of $2,664,955.60. Following the sale, the insider now directly owns 3,238,199 shares in the company, valued at $51,325,454.15. This trade represents a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 22.20% of the stock is owned by corporate insiders.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.